Dynamic Technology Lab Private Ltd Invests $242,000 in Celldex Therapeutics, Inc. (CLDX)

Dynamic Technology Lab Private Ltd acquired a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 84,548 shares of the biopharmaceutical company’s stock, valued at approximately $242,000. Dynamic Technology Lab Private Ltd owned 0.07% of Celldex Therapeutics at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Ameriprise Financial Inc. grew its stake in shares of Celldex Therapeutics by 15.6% during the 3rd quarter. Ameriprise Financial Inc. now owns 441,411 shares of the biopharmaceutical company’s stock worth $1,263,000 after purchasing an additional 59,629 shares during the period. Russell Investments Group Ltd. grew its stake in shares of Celldex Therapeutics by 741.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 352,511 shares of the biopharmaceutical company’s stock worth $1,008,000 after purchasing an additional 310,638 shares during the period. Bank of New York Mellon Corp grew its stake in shares of Celldex Therapeutics by 3.6% during the 3rd quarter. Bank of New York Mellon Corp now owns 622,430 shares of the biopharmaceutical company’s stock worth $1,780,000 after purchasing an additional 21,905 shares during the period. Meditor Group Ltd grew its stake in shares of Celldex Therapeutics by 8.8% during the 3rd quarter. Meditor Group Ltd now owns 6,312,700 shares of the biopharmaceutical company’s stock worth $18,054,000 after purchasing an additional 512,700 shares during the period. Finally, California State Teachers Retirement System grew its stake in shares of Celldex Therapeutics by 13.9% during the 2nd quarter. California State Teachers Retirement System now owns 214,400 shares of the biopharmaceutical company’s stock worth $530,000 after purchasing an additional 26,200 shares during the period. 52.55% of the stock is currently owned by institutional investors and hedge funds.

Celldex Therapeutics, Inc. (CLDX) opened at $2.86 on Thursday. Celldex Therapeutics, Inc. has a fifty-two week low of $2.20 and a fifty-two week high of $4.07.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.07. The company had revenue of $3.90 million for the quarter, compared to analyst estimates of $1.30 million. Celldex Therapeutics had a negative return on equity of 46.94% and a negative net margin of 1,088.58%. The firm’s revenue for the quarter was up 77.3% on a year-over-year basis. During the same quarter last year, the firm posted ($0.29) EPS. equities research analysts expect that Celldex Therapeutics, Inc. will post -0.93 EPS for the current fiscal year.

A number of equities research analysts have recently commented on CLDX shares. HC Wainwright set a $10.00 price objective on shares of Celldex Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, August 9th. ValuEngine lowered Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Cantor Fitzgerald reiterated a “buy” rating and set a $9.00 target price on shares of Celldex Therapeutics in a research report on Tuesday, September 26th. Finally, WBB Securities reiterated a “buy” rating and set a $10.00 target price on shares of Celldex Therapeutics in a research report on Wednesday. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. Celldex Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $7.05.

COPYRIGHT VIOLATION NOTICE: This piece was posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3078823/dynamic-technology-lab-private-ltd-invests-242000-in-celldex-therapeutics-inc-cldx.html.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX).

Institutional Ownership by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.